$STXS
Stereotaxis, Inc. Stock $stxs

$stxs Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223016720 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$7.859M	$6.548M	$7.037M
YoY Change	27.75%	-6.95%	-18.39%
Cost Of Revenue	$3.672M	$2.672M	$2.113M
YoY Change	147.77%	26.46%	-18.94%
Gross Profit	$4.187M	$3.876M	$4.924M
YoY Change	-10.34%	-21.28%	-18.15%
Gross Profit Margin	53.28%	59.19%	69.97%
Selling, General & Admin	$6.817M	$6.749M	$6.566M
YoY Change	-2.0%	2.79%	26.83%
% of Gross Profit	162.81%	174.12%	133.35%
Research & Development	$2.647M	$2.746M	$2.447M
YoY Change	-8.5%	12.22%	3.38%
% of Gross Profit	63.22%	70.85%	49.7%
Depreciation & Amortization	$150.0K	$160.0K	$100.0K
YoY Change	59.57%	60.0%	272.86%
% of Gross Profit	3.58%	4.13%	2.03%
Operating Expenses	$9.464M	$9.495M	$9.013M
YoY Change	-3.91%	5.35%	19.47%
Operating Profit	-$5.277M	-$5.619M	-$4.089M
YoY Change	1.89%	37.42%	167.58%
Interest Expense	$293.0K	$272.0K	$3.000K
YoY Change	551.11%	8966.67%	-170.09%
% of Operating Profit
Other Income/Expense, Net	$27.00K
YoY Change
Pretax Income	-$4.957M	-$5.347M	-$4.086M
YoY Change	-3.45%	30.86%	166.64%
Income Tax
% Of Pretax Income
Net Earnings	-$4.957M	-$5.347M	-$4.086M
YoY Change	-3.45%	30.86%	166.64%
Net Earnings / Revenue	-63.07%	-81.66%	-58.06%
Basic Earnings Per Share	-$0.07	-$0.07	-$0.06
Diluted Earnings Per Share	-$0.07	-$0.07	-$53.85K
COMMON SHARES
Basic Shares Outstanding	80.68M shares	75.05M shares	75.88M shares
Diluted Shares Outstanding	81.05M shares	76.50M shares	75.88M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$22.88M	$25.66M	$35.10M
YoY Change	-31.71%	-26.87%	-17.33%
Cash & Equivalents	$22.88M	$5.623M	$35.10M
Short-Term Investments	$0.00	$20.04M
Other Short-Term Assets	$1.677M	$1.857M	$2.496M
YoY Change	4.23%	-25.6%	-23.47%
Inventory	$7.703M	$8.510M	$4.850M
Prepaid Expenses
Receivables	$6.645M	$4.874M	$4.693M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$38.90M	$40.91M	$47.13M
YoY Change	-16.59%	-13.22%	-16.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.590M	$3.722M	$8.904M
YoY Change	10.12%	-58.2%	369.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$635.0K	$796.0K	$1.391M
YoY Change	-48.12%	-42.77%	267.72%
Total Long-Term Assets	$9.413M	$9.806M	$10.30M
YoY Change	-6.22%	-4.75%	352.24%
TOTAL ASSETS
Total Short-Term Assets	$38.90M	$40.91M	$47.13M
Total Long-Term Assets	$9.413M	$9.806M	$10.30M
Total Assets	$48.32M	$50.71M	$57.43M
YoY Change	-14.76%	-11.7%	-2.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.840M	$3.535M	$2.892M
YoY Change	-33.08%	22.23%	27.38%
Accrued Expenses	$2.920M	$2.804M	$2.063M
YoY Change	37.35%	35.92%	-52.17%
Deferred Revenue	$8.223M	$7.545M
YoY Change	18.16%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.38M	$14.27M	$11.49M
YoY Change	5.31%	24.18%	-31.14%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$43.00K	$51.00K	$8.032M
YoY Change	-78.71%	-99.37%	422.11%
Total Long-Term Liabilities	$43.00K	$51.00K	$8.032M
YoY Change	-78.71%	-99.37%	350.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.38M	$14.27M	$11.49M
Total Long-Term Liabilities	$43.00K	$51.00K	$8.032M
Total Liabilities	$21.35M	$21.42M	$19.52M
YoY Change	0.92%	9.71%	5.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$527.3M	-$522.3M
YoY Change	3.81%
Common Stock	$81.00K	$75.00K
YoY Change	8.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.39M	$23.71M	$32.32M
YoY Change
Total Liabilities & Shareholders Equity	$48.32M	$50.71M	$57.43M
YoY Change	-14.76%	-11.7%	-2.36%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$4.957M	-$5.347M	-$4.086M
YoY Change	-3.45%	30.86%	166.64%
Depreciation, Depletion And Amortization	$150.0K	$160.0K	$100.0K
YoY Change	59.57%	60.0%	272.86%
Cash From Operating Activities	-$2.931M	-$2.802M	-$2.193M
YoY Change	157.78%	27.77%	618.62%
INVESTING ACTIVITIES
Capital Expenditures	$7.000K	$349.0K	-$1.154M
YoY Change	-101.08%	-130.24%	3275.26%
Acquisitions
YoY Change
Other Investing Activities	$20.13M
YoY Change
Cash From Investing Activities	$20.12M	-$349.0K	-$1.154M
YoY Change	-3196.0%	-69.76%	3275.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-26.00K	$56.00K	54.00K
YoY Change	-145.61%	3.7%	-80.84%
NET CHANGE
Cash From Operating Activities	-2.931M	-$2.802M	-2.193M
Cash From Investing Activities	20.12M	-$349.0K	-1.154M
Cash From Financing Activities	-26.00K	$56.00K	54.00K
Net Change In Cash	17.17M	-$3.095M	-3.293M
YoY Change	-1092.31%	-6.01%	5629.95%
FREE CASH FLOW
Cash From Operating Activities	-$2.931M	-$2.802M	-$2.193M
Capital Expenditures	$7.000K	$349.0K	-$1.154M
Free Cash Flow	-$2.938M	-$3.151M	-$1.039M
YoY Change	503.29%	203.27%	283.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001289340
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments		usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-36159
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	STEREOTAXIS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3120386
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	710 North Tucker Boulevard
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 110
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	235000	usd
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	St. Louis
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MO
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	63101
CY2023Q1	dei	City Area Code CityAreaCode	(314)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	678-6100
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	STXS
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4874000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5090000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	8510000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	7876000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1332000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1325000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	40905000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	43246000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3722000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3831000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	612000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	744000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5288000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5384000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	184000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	208000	usd
CY2023Q1	us-gaap	Assets Assets	50711000	usd
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q4	us-gaap	Assets Assets	53413000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3535000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3270000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2804000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3306000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7545000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7342000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	385000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	373000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	14269000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14291000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1711000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1654000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5387000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5488000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	51000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	51000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	21418000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	21484000	usd
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	22383	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	22383	shares
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	5583000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	5583000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5610121	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5610121	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	6000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	6000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75059499	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74874459	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	75000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	75000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	546149000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	543438000	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4015	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4015	shares
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	206000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	206000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-522314000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-516967000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	23710000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26346000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50711000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53413000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6548000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7037000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	2672000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	2113000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	3876000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	4924000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2746000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2447000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3148000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2946000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3601000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3620000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	9495000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	9013000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5619000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4089000	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	272000	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	3000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5347000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4086000	usd
CY2023Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	331000	usd
CY2022Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	331000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5678000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4417000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	76500965	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75877391	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	76500965	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75877391	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	33840000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	18000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2514000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4086000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	36000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	32322000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26346000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	33000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2655000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5347000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	23000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	23710000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5347000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4086000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	160000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	100000	usd
CY2023Q1	STXS	Operating Lease Expense Income OperatingLeaseExpenseIncome	7000	usd
CY2022Q1	STXS	Operating Lease Expense Income OperatingLeaseExpenseIncome	33000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2655000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2514000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	197000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-216000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-713000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	97000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	417000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-478000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-24000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-25000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	563000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-871000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1547000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-561000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	768000	usd
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	80678375	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5623000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8586000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	525000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	525000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	20041000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	19844000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-104000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	341000	usd
CY2023Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-17000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2802000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2193000	usd
CY2023Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	349000	usd
CY2022Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1154000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-349000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1154000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	54000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	56000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3095000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3293000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9855000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40144000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6760000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36851000	usd
CY2023Q1	STXS	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities	15000	usd
CY2022Q1	STXS	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities	699000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5623000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35095000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	525000	usd
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	618000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	612000	usd
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1138000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	6760000	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	36851000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_808_eus-gaap--NatureOfOperations_z4tXpi0STjZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>1. <span id="xdx_820_z7Ht5EA9PZh2">Description of Business</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stereotaxis designs, manufactures and markets robotic systems, instruments and information systems for the interventional laboratory. Our proprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Direct control of the tip of an interventional device, in contrast to all manual hand-held devices that are controlled from their handle, can improve the precision, stability, reach and safety of these devices during procedures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our primary clinical focus has been electrophysiology, specifically cardiac ablation procedures for the treatment of arrhythmias. Cardiac ablation has become a well-accepted therapy for arrhythmias and a multi-billion-dollar medical device market with expectations for substantial long-term growth. We have shared our aspiration and a product strategy to expand the clinical focus of our technology to several additional endovascular indications including coronary, neuro, and peripheral interventions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is substantial real-world evidence and clinical literature for Robotic Magnetic Navigation in electrophysiology. Hundreds of electrophysiologists at over one hundred hospitals globally have treated over 100,000 arrhythmia patients with our robotic technology. Clinical use of our technology has been documented in over 400 clinical publications. Robotic Magnetic Navigation is designed to enable physicians to complete more complex interventional procedures with greater success and safety by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied computer-controlled magnetic fields that govern the motion of the working tip of the catheter, resulting in improved navigation. The more flexible atraumatic design of catheters driven using magnetic fields may reduce the risk of patient harm and other adverse events. Performing the procedure from a control cockpit enables physicians to complete procedures in a safe location protected from x-ray exposure, with greater ergonomics, and improved efficiency. We believe these benefits can be applicable in other endovascular indications where navigation through complex vasculature is often challenging or unsuccessful and generates significant x-ray exposure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our primary products include the <i>Genesis RMN </i>System, the <i>Odyssey </i>Solution, and other related devices. We also offer our customers the Stereotaxis Imaging Model S x-ray System and other accessory devices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <i>Genesis RMN System</i> is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter, resulting in improved navigation, efficient procedures, and reduced x-ray exposure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <i>Odyssey Solution</i> consolidates lab information onto one large integrated display, enabling physicians to view and control all the key information in the operating room. This is designed to improve lab layout and procedure efficiency. The system also features a remote viewing and recording capability called <i>Odyssey Cinema,</i> which is an innovative solution that delivers synchronized content for optimized workflow, advanced care, and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation, and training.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Stereotaxis Imaging Model S provides an integrated complete solution for a robotic interventional operating room. It is a single-plane, full-power x-ray system and includes the c-arm, powered table, motorized boom, and large high-definition monitors. Stereotaxis Imaging Model S incorporates modern fluoroscopy technology to support high quality imaging while minimizing radiation exposure for patients and physicians. The combination of RMN Systems with Stereotaxis Imaging Model S is designed to reduce the cost of acquisition, the ongoing cost of ownership, and the complexity of installation of a robotic electrophysiology practice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We promote our full suite of products in a typical hospital implementation, subject to regulatory approvals or clearances. This implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and ongoing software updates. In hospitals where our full suite of products has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have received regulatory clearances and registration necessary for us to market the <i>Genesis RMN</i> System in the U.S. and Europe, and we are in the process of obtaining necessary registrations for extending our markets in other countries. Our prior generation robotic magnetic navigation system, the <i>Niobe</i> System, the <i>Odyssey</i> Solution, <i>Cardiodrive</i>, and various disposable interventional devices have received regulatory clearance in the U.S., Europe, Canada, China, Japan and various other countries. We have received the regulatory clearance, licensing and/or CE Mark approvals that allow us to market the <i>Vdrive</i> and <i>Vdrive Duo</i> Systems with the <i>V-CAS</i>, <i>V-Loop </i>and <i>V-Sono</i> devices in the U.S., Canada and Europe. The Stereotaxis Imaging Model S x-ray System is CE marked and cleared by the FDA.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have strategic relationships with technology leaders and innovators in the global interventional market. Through these strategic relationships we provide compatibility between our robotic magnetic navigation system and digital imaging and 3D catheter location sensing technology, as well as disposable interventional devices. The maintenance of these strategic relationships, or the establishment of equivalent alternatives, is critical to our commercialization efforts. There are no guarantees that any existing strategic relationships will continue, and efforts are ongoing to ensure the availability of integrated systems and devices and/or equivalent alternatives. We cannot provide assurance as to the timeline of the ongoing availability of such compatible systems or our ability to obtain equivalent alternatives on competitive terms or at all.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zz5LQWVjoRkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i><span id="xdx_861_zrAqsn8yCUv5">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our investments may include, at any time, a diversified portfolio of cash equivalents and short-term and long-term investments in a variety of high-quality securities, including money market funds, U.S. treasury and U.S. government agency securities, corporate notes and bonds, commercial paper, non-U.S. government agency securities, and municipal notes. <span style="background-color: white">The Company’s exposure to any individual corporate entity is limited by policy. Deposits may exceed federally insured limits, and the Company is exposed to credit risk on deposits in the event of default by the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation (FDIC). The Company is closely monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, including Silicon Valley Bank. On March 10, 2023, Silicon Valley Bank (“SVB”), where the Company maintained accounts with a cash balance of less than <span id="xdx_904_ecustom--CashBalancePercentage_iI_pid_dp_uPure_c20230310_z0Ej6OEdEDx2" title="Minimum cash balance percentage">6%</span> of the Company’s total cash, cash equivalents and marketable securities, was closed by the California Department of Financial Protection and Innovation and the FDIC was appointed as receiver. On March 12, 2023, the U.S. Department of the Treasury, Federal Reserve Board, and FDIC released a joint statement announcing that the FDIC would complete its resolution of SVB in a manner that fully protected all depositors at SVB and that depositors would have access to all of their money starting March 13, 2023. On March 26, 2023, it was announced that First-Citizens Bank & Trust Company would assume all of SVB’s deposits and loans as of March 27, 2023. The Company does not believe that it has exposure to loss as a result of SVB’s receivership. During the periods presented, the Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	STXS	Cash Balance Percentage CashBalancePercentage	0.06	pure
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	1100000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	1300000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6548000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7037000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	15100000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	659000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	539000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	9256000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8996000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1711000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1654000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7545000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7342000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3000000.0	usd
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3200000	usd
CY2023Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	331000	usd
CY2022Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	331000	usd
CY2023Q1	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	200000	usd
CY2022Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	200000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.76	pure
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5347000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4086000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5678000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4417000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	76500965	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75877391	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2023Q1	us-gaap	Cash Cash	1256000	usd
CY2023Q1	us-gaap	Cash Cash	1256000	usd
CY2023Q1	us-gaap	Cash Cash	1256000	usd
CY2023Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	26801000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	3000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	5000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	26799000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5623000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	525000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	20041000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	612000	usd
CY2022Q4	us-gaap	Cash Cash	3258000	usd
CY2022Q4	us-gaap	Cash Cash	3258000	usd
CY2022Q4	us-gaap	Cash Cash	3258000	usd
CY2022Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	29699000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	2000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	8000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	29693000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8586000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	525000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	19844000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	744000	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	7760000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6556000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	425000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	530000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2270000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2697000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1945000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1907000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	8510000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	7876000	usd
CY2023Q1	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	730000	usd
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	605000	usd
CY2023Q1	STXS	Prepaid Commissions Current And Noncurrent PrepaidCommissionsCurrentAndNoncurrent	167000	usd
CY2022Q4	STXS	Prepaid Commissions Current And Noncurrent PrepaidCommissionsCurrentAndNoncurrent	187000	usd
CY2023Q1	us-gaap	Deposits Assets DepositsAssets	528000	usd
CY2022Q4	us-gaap	Deposits Assets DepositsAssets	669000	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	91000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	72000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1516000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1533000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	184000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	208000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1332000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1325000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7340000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7289000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3618000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3458000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3722000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3831000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	100000	usd
CY2022	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	1200000	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5900000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y8M26D
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	227000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	226000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	4000	usd
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	10000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	231000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	236000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	242000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	434000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	659000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	898000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	919000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	935000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	956000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4030000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8397000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2625000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	5772000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	899000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	1381000	usd
CY2023Q1	STXS	Accrued Licenses And Maintenance Fees Current And Noncurrent AccruedLicensesAndMaintenanceFeesCurrentAndNoncurrent	484000	usd
CY2022Q4	STXS	Accrued Licenses And Maintenance Fees Current And Noncurrent AccruedLicensesAndMaintenanceFeesCurrentAndNoncurrent	484000	usd
CY2023Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	155000	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	163000	usd
CY2023Q1	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	75000	usd
CY2022Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	47000	usd
CY2023Q1	STXS	Accrued Investigational Sites AccruedInvestigationalSites	85000	usd
CY2022Q4	STXS	Accrued Investigational Sites AccruedInvestigationalSites	101000	usd
CY2023Q1	us-gaap	Contractual Obligation ContractualObligation	1045000	usd
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	1045000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	112000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	136000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2855000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	3357000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	51000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	51000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2804000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3306000	usd
CY2023Q1	us-gaap	Common Stock Voting Rights CommonStockVotingRights	The holders of common stock are entitled to one vote for each share held
CY2023Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	0	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5500000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3208065	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.21
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	697000	shares
CY2023Q1	STXS	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Granted SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceGranted	2.57
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.57
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	29188	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.15
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	62671	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.62
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3813206	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.95
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	163000	usd
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	242000	usd
CY2023Q1	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	7000	usd
CY2022	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	113000	usd
CY2023Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	15000	usd
CY2022	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	192000	usd
CY2023Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	155000	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	163000	usd

Files In Submission

Name	View Source	Status
0001493152-23-016720-index-headers.html	Edgar Link	pending
0001493152-23-016720-index.html	Edgar Link	pending
0001493152-23-016720.txt	Edgar Link	pending
0001493152-23-016720-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stxs-20230331.xsd	Edgar Link	pending
stxs-20230331_cal.xml	Edgar Link	unprocessable
stxs-20230331_def.xml	Edgar Link	unprocessable
stxs-20230331_lab.xml	Edgar Link	unprocessable
stxs-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STXS
Stereotaxis, Inc. Stock $stxs

2023 Q2 Form 10-Q Financial Statement

#000149315223016720 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STXS Stereotaxis, Inc. Stock $stxs

2023 Q2 Form 10-Q Financial Statement

#000149315223016720 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STXS
Stereotaxis, Inc. Stock $stxs